title: Pneumocystis jirovecii pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept.
abstract: A 66-year-old woman who had rheumatoid arthritis and underwent a long-term treatment with methotrexate and etanercept developed Pneumocystis jirovecii pneumonia (PCP) 3 months after iguratimod add-on. Although most rheumatologists might have the impression that iguratimod has less toxicity and immunosuppressive effect compared with methotrexate and biologic disease-modifying antirheumatic drugs, this case suggests that iguratimod may increase the risk of PCP, especially in combination with other drugs.
authors.affiliation: a Department of Internal Medicine , Kawasaki Municipal Kawasaki Hospital , Kawasaki , Japan and.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Arita
authors.affiliation: b Center for Arthritis and Rheumatic Diseases , Kawasaki Municipal Kawasaki Hospital , Kawasaki , Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Taguchi
authors.affiliation: a Department of Internal Medicine , Kawasaki Municipal Kawasaki Hospital , Kawasaki , Japan and.
authors.forename: Mari
authors.initials: M
authors.lastname: Kobayashi
authors.affiliation: b Center for Arthritis and Rheumatic Diseases , Kawasaki Municipal Kawasaki Hospital , Kawasaki , Japan.
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Tono
authors.affiliation: b Center for Arthritis and Rheumatic Diseases , Kawasaki Municipal Kawasaki Hospital , Kawasaki , Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ohsone
authors.affiliation: b Center for Arthritis and Rheumatic Diseases , Kawasaki Municipal Kawasaki Hospital , Kawasaki , Japan.
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Okano
mesh_terms: D000368:Aged; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D002867:Chromones / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000379:methods; D000068800:Etanercept / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D000069451:Long Term Adverse Effects / Q000209:etiology / Q000276:immunology; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D045363:Pneumocystis carinii / Q000302:isolation & purification*; D011020:Pneumonia, Pneumocystis / Q000209:etiology / Q000276:immunology; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D018501:Antirheumatic Agents; D002867:Chromones; D007166:Immunosuppressive Agents; D013449:Sulfonamides; C519076:iguratimod; D000068800:Etanercept; D008727:Methotrexate
keywords: Disease-modifying antirheumatic drug; Iguratimod; Pneumocystis jirovecii pneumonia; Rheumatoid arthritis